The legacy success of sildenafil has undeniably transformed the pharmaceutical landscape. However, wagering in companies heavily dependent on biosimilars and the declining patent exclusivity surrounding https://myeasybookmarks.com/story7027712/the-blue-pill-and-drugmakers-a-risky-venture